OSI-774 in African American Patients With Advanced and Previously Treated Non-Small Cell Lung Cancer

• Status: Completed
• Trial end date: 2013-07-01
• Target enrollment: 0
• Participant gender: All

Summary

This study determines tumor response rate, time to tumor progression and survival rate at 1 year produced by OSI-774 in previously treated African American patients with nonsmall cell lung cancer.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Miguel Villalona; Ohio State University Comprehensive Cancer Center
• Collaborator: Genentech, Inc.
• Treatments: Erlotinib Hydrochloride

Criteria

Inclusion Criteria:

• Must have histologically or cytologically confirmed stage IIIB or IV NSCLC treated with 1-2 platinum- or taxane-containing regimens

• Measurable disease

• May have had prior surgery & external beam radiation

• African American

• 18 years or older

Exclusion Criteria:

• Known brain mets

• Prior treatment with EGFR targeting therapies

• Pregnant/lactating women